FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

被引：0

作者：

Moore, K. ^{[1
]}

Oza, A. ^{[2
]}

Colombo, N. ^{[3
,4
]}

Oaknin, A. ^{[5
]}

Scambia, G. ^{[6
]}

Lorusso, D. ^{[7
]}

Farias-Eisner, R. ^{[8
]}

Banerjee, S. ^{[9
]}

Murphy, C. ^{[10
]}

Tanyi, J. ^{[11
]}

Hirte, H. ^{[12
]}

Konner, J. ^{[13
]}

Lim, P. ^{[14
]}

Hayes, M. Prasad ^{[15
]}

Monk, B. ^{[16
]}

Kim, S. ^{[17
]}

Wang, J. ^{[18
]}

Pautier, P. ^{[19
]}

Vergote, I. ^{[20
]}

Birrer, M. ^{[21
]}

机构：

[1] Univ Oklahoma, Dept Obstet & Gynecol Univ, Stephenson Canc Ctr, Oklahoma City, OK USA

[2] Univ Hlth Network, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada

[3] European Inst Oncol, Dept Gynecol Oncol, Milan, Italy

[4] Univ Milano Bicocca, Milan, Italy

[5] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain

[6] Univ Cattolica, Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy

[7] Fdn IRCCS Ist Nazl Tumori, Gynecol Oncol, Milan, Italy

[8] Univ Calif Los Angeles, Dept Obstet & Gynecol, Los Angeles, CA 90024 USA

[9] Royal Marsden Hosp NHS Fdn Trust, Gynaecol, London, England

[10] Bon Secours Hosp, Med Oncol, Cork, Ireland

[11] Univ Penn, Obstet & Gynecol, Philadelphia, PA 19104 USA

[12] Juravinski Canc Ctr, Oncol, Hamilton, ON, Canada

[13] Mem Sloan Kettering Canc Ctr, Gynecol Oncol, 1275 York Ave, New York, NY 10021 USA

[14] Ctr Hope, Gynecol Oncol, Reno, NV USA

[15] Icahn Sch Med Mt Sinai, Obstet & Gynecol, New York, NY 10029 USA

[16] Creighton Univ, Univ Arizona, St Josephs Hosp, Gynecol Oncol,Arizona Oncol,Coll Med,Sch Med, Phoenix, AZ USA

[17] Univ Texas Houston, McGovern Med Sch, Houston, TX USA

[18] ImmunoGen Inc, Clin Dev, Waltham, MA USA

[19] Gustave Roussy, Med, Villejuif, France

[20] Univ Hosp Leuven Campus Gasthuisberg, Gynaecol, Leuven, Belgium

[21] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, MA USA

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

992O

引用

页数：1

共 50 条

[1] Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
O'Malley, David M.
Matulonis, Ursula A.
Birrer, Michael J.
Castro, Cesar M.
Gilbert, Lucy
Vergote, Ignace
Martin, Lainie P.
Mantia-Smaldone, Gina M.
Gonzalez Martin, Antonio
Bratos, Raquel
Penson, Richard T.
Malek, Karim
Moore, Kathleen N.
GYNECOLOGIC ONCOLOGY, 2020, 157 (02) : 379 - 385
[2] PHASE I EXPANSION STUDY OF MIRVETUXIMAB SORAVTANSINE, A FOLATE RECEPTOR ALPHA (FRa)-TARGETING ANTIBODY-DRUG CONJUGATE (ADC), IN PATIENTS WITH ENDOMETRIAL CANCER
Martin, L.
Konner, J.
O'Malley, D.
Bauer, T.
Matulonis, U.
Seward, S.
Oza, A.
Kirby, M.
Birrer, M.
Moore, K.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1975 - 1975
[3] Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR?)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
Gilbert, Lucy
Oaknin, Ana
Matulonis, Ursula A.
Mantia-Smaldone, Gina M.
Lim, Peter C.
Castro, Cesar M.
Provencher, Diane
Memarzadeh, Sanaz
Method, Michael
Wang, Jiuzhou
Moore, Kathleen N.
O'Malley, David M.
GYNECOLOGIC ONCOLOGY, 2023, 170 : 241 - 247
[4] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial results of an expansion cohort from FORWARD II, a phase Ib study
Matulonis, U. A.
Moore, K. N.
Martin, L. P.
Vergote, I. B.
Castro, C.
Gilbert, L.
Malek, K.
Birrer, M. J.
O'Malley, D. M.
ANNALS OF ONCOLOGY, 2018, 29
[5] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study.
O'Malley, David M.
Matulonis, Ursula A.
Birrer, Michael J.
Castro, Cesar Martin
Vergote, Ignace
Martin, Lainie P.
Mantia-Smaldone, Gina
Gilbert, Lucy
Gonzalez-Martin, Antonio
Bratos, Raquel
Esteves, Brooke
Malek, Karim S.
Moore, Kathleen N.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[6] FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer
Moore, Kathleen N.
Vergote, Ignace
Oaknin, Ana
Colombo, Nicoletta
Banerjee, Susana
Oza, Amit
Pautier, Patricia
Malek, Karim
Birrer, Michael J.
FUTURE ONCOLOGY, 2018, 14 (17) : 1669 - 1678
[7] Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a phase Ib study in patients (pts) with ovarian cancer
O'Malley, D.
Richardson, D.
Vergote, I. B.
Gilbert, L.
Martin, L. P.
Mantia-Smaldone, G. M.
Castro, C.
Provencher, D.
Matulonis, U. A.
Malek, K.
Moore, K. N.
ANNALS OF ONCOLOGY, 2019, 30
[8] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer.
Gilbert, Lucy
Oaknin, Ana
Matulonis, Ursula A.
Mantia-Smaldone, Gina
Lim, Peter C.
Castro, Cesar Martin
Provencher, Diane M.
Memarzadeh, Sanaz
Wang, Jiuzhou
Esteves, Brooke
Zweidler-McKay, Patrick A.
Moore, Kathleen N.
O'Malley, David M.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[9] Initial safety and activity findings froma phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients
Matulonis, U. A.
Moore, K. N.
Martin, L. P.
Vergote, I. B.
Castro, C. M.
Gilbert, L.
Berkenblit, A.
Birrer, M. J.
O'Malley, D. M.
GYNECOLOGIC ONCOLOGY, 2018, 149 : 38 - 38
[10] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Maturing safety and activity profile from the FORWARD II phase 1b study.
O'Malley, David M.
Martin, Lainie P.
Gilbert, Lucy
Vergote, Ignace
Matulonis, Ursula A.
Birrer, Michael J.
Castro, Cesar Martin
Malek, Karim S.
Gonzalez-Martin, Antonio
Moore, Kathleen N.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →